However, intra-tumoral heterogeneity produces functional subpopulations, including STIC and TMC, with different levels of EGFR expression, and decades-long trials with anti-EGFR agents have failed to improved GBM patient outcomes [4]. This evidence concerns the gene EGFR and glioblastoma.